Odonate Therapeutics announces completion of enrollment in CONTESSA metastatic breast cancer trial

Odonate Therapeutics, a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the completion of enrollment in CONTESSA, a multinational, multicenter, randomized, Phase 3 study investigating tesetaxel as a potential treatment for patients with HER2 negative, hormone receptor positive metastatic breast cancer. The Company expects to report top-line results from CONTESSA in the third quarter of 2020.